Results
A total of 180 patients were enrolled and randomized, with 119 patients in the durvalumab plus tremelimumab group and 61 in the BSC group. The median age was 65 years (range, 36-87 years); there were 121 men (67.2%) and 59 women (32.8%). In terms of race and ethnicity, 19 patients (10.6%) were Asian, 151 (83.9%) were White, and 10 (5.6%) were of other race or ethnicity. At the time of study entry, LM were present in 127 patients (70.6%), including 80 of 119 (67.2%) in the durvalumab plus tremelimumab group and 47 of 61 (77.0%) in the BSC group (